Complete Blood Count (CBC) is the Essential Test for Monitoring Zidovudine Side Effects
The complete blood count (CBC) is the diagnostic test required to assess zidovudine's primary side effect of bone marrow suppression, which manifests as anemia and neutropenia. 1
Why CBC is Critical for Zidovudine Monitoring
The FDA drug label for Retrovir (zidovudine) explicitly states that "frequent blood counts are strongly recommended to detect severe anemia or neutropenia" in patients treated with zidovudine 1. This is because:
Hematologic Toxicity Profile
- Anemia develops early: Reduction in hemoglobin can occur as early as 2-4 weeks after starting therapy
- Neutropenia follows: Typically occurs after 6-8 weeks of treatment
- Pancytopenia is possible: All blood cell lines can be affected, though this is reversible after drug discontinuation in most cases 1
Monitoring Frequency Requirements
The FDA label specifies different monitoring intensities based on disease severity:
- Advanced HIV disease with poor bone marrow reserve: Frequent blood counts are strongly recommended
- Asymptomatic or early HIV disease: Periodic blood counts are recommended 1
Why the Other Tests Are Not Appropriate
- Hemoglobin A1C: Used for diabetes screening, not relevant to zidovudine toxicity monitoring
- Immunodeficiency panel: Assesses immune function (CD4 counts), not bone marrow suppression
- Serum glucose: Monitors for metabolic complications, not hematologic toxicity
Clinical Context for Older Adults
This is particularly important in elderly patients because:
- They may have pre-existing bone marrow compromise
- The drug label warns against use in patients with granulocyte count <1,000 cells/mm³ or hemoglobin <9.5 g/dL 1
- Dose interruption may be needed if anemia or neutropenia develops
Contemporary Practice Note
While current HIV guidelines 2 suggest that routine hematologic monitoring may not be necessary with modern first-line antiretroviral regimens (which rarely include zidovudine), zidovudine specifically requires CBC monitoring due to its well-established bone marrow toxicity 1, 3. A 2024 case report documented severe aplastic anemia occurring even after 11 years of zidovudine use, emphasizing the need for ongoing monitoring throughout therapy 3.
The answer is: Complete blood count.